Morgan Stanley analyst Judah Frommer maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) yesterday and set a price target of $36.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Judah Frommer’s rating is based on the promising clinical progress of Bicara Therapeutics’ lead candidate, ficerafusp alfa. The company has shown encouraging results in their studies, particularly in the treatment of head and neck squamous cell carcinoma (HNSCC), with upcoming data expected to further demonstrate the drug’s efficacy and durability. The anticipation of updated survival and response data at the upcoming ASCO conference adds to the positive outlook.
Additionally, Bicara is advancing its programs in other HNSCC populations and solid tumors, with ongoing and planned clinical trials exploring various dosing regimens. The company’s strategic focus on expanding its clinical pipeline and the potential for significant developments in their studies contribute to the Buy rating. Furthermore, the company’s financial position, with a cash runway extending into the first half of 2029, supports its ability to continue its research and development efforts.